A preponderance of evidence from the FDA cVAD Study, Impella Quality Assurance Database and physician-initiated National Cardiogenic Shock Initiative support the recommendation that placing Impella 2.5 or Impella CP pre-PCI improves outcomes.
Category: Cardiogenic Shock
Use this FDA-approved checklist to guide treatment decisions and determine if the Impella RP is right for your patients. IMP-574
Adoption of best practices improves survival for patients with Acute Myocardial Infarction and Cardiogenic Shock (AMICS) supported with Impella.
The Impella 5.0 is approved for use in cardiogenic shock, and is proven to unload the left ventricle and support the systemic circulation.
For patients in post cardiotomy cardiogenic shock (PCCS), the Impella LD can assist in the efforts to successfully unload the left ventricle and separate from bypass while offering full systemic circulatory support.
The Impella RP is the only FDA approved support device for the treatment of right heart failure.
The Impella 2.5®, Impella CP® and Impella 5.0®/ Impella LD® Heart Pumps and Impella RP® Heart Pump, in conjunction with the Automated Impella® Controller (AIC), are temporary ventricular support devices intended for short term use and indicated for the treatment of ongoing cardiogenic shock that occurs immediately following acute myocardial infarction or open heart surgery … Continue reading “Abiomed Cardiogenic Shock Protocol”
Impella 2.5®, Impella CP®, Impella 5.0®, and Impella LD® heart pumps are now FDA indicated to provide treatment of ongoing cardiogenic shock. In this setting, the Impella® heart pumps have the ability to stabilize the patient’s hemodynamics, unload the left ventricle, perfuse the end organs, and allow for recovery of the native heart.